Ultragenyx Pharmaceutical Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending March 31, 2025: USD 399.46 M

Ultragenyx Pharmaceutical Inc. Net Cash Used Provided By Financing Activities is USD 399.46 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 2.74% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • Ultragenyx Pharmaceutical Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 388.81 M, a -22.06% change year over year.
  • Ultragenyx Pharmaceutical Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 498.87 M, a 364.00% change year over year.
  • Ultragenyx Pharmaceutical Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 107.52 M, a -80.71% change year over year.
  • Ultragenyx Pharmaceutical Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 557.31 M, a 46.16% change year over year.
Key Data
Date Net Cash Used Provided By Financing Activities Depreciation And Amortization Dividends Paid Common Stock Issued